{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:55:44Z","timestamp":1777294544371,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82274582"],"award-info":[{"award-number":["No. 82274582"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40120-025-00861-4","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:46:18Z","timestamp":1763538378000},"page":"179-192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efgartigimod Combined with Glucocorticoids in the Treatment of Severe Generalized Myasthenia Gravis: A Single-Center, Retrospective Cohort Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Shanshan","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengna","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congya","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9218-3219","authenticated-orcid":false,"given":"Guoyan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"861_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1212\/WNL.0b013e3181ad53c2","volume":"73","author":"AT Heldal","year":"2009","unstructured":"Heldal AT, Owe JF, Gilhus NE, et al. Seropositive myasthenia gravis: a nationwide epidemiologic study. Neurology. 2009;73:150\u20131. https:\/\/doi.org\/10.1212\/WNL.0b013e3181ad53c2.","journal-title":"Neurology"},{"key":"861_CR2","first-page":"82","volume":"67","author":"A R\u00f8dgaard","year":"1987","unstructured":"R\u00f8dgaard A, Nielsen FC, Djurup R, et al. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol. 1987;67:82\u20138.","journal-title":"Clin Exp Immunol"},{"key":"861_CR3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","volume":"205","author":"TM Hendricks","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, et al. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol. 2019;205:99\u2013105. https:\/\/doi.org\/10.1016\/j.ajo.2019.04.017.","journal-title":"Am J Ophthalmol"},{"key":"861_CR4","doi-asserted-by":"publisher","first-page":"175628641987652","DOI":"10.1177\/1756286419876521","volume":"12","author":"M Li","year":"2019","unstructured":"Li M, Ge F, Guo R, et al. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2019;12:1756286419876521. https:\/\/doi.org\/10.1177\/1756286419876521.","journal-title":"Ther Adv Neurol Disord"},{"key":"861_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/1941875210382918","volume":"1","author":"LC Wendell","year":"2011","unstructured":"Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011;1:16\u201322. https:\/\/doi.org\/10.1177\/1941875210382918.","journal-title":"Neurohospitalist"},{"key":"861_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16180","volume":"31","author":"F Sacc\u00e0","year":"2024","unstructured":"Sacc\u00e0 F, Salort-Campana E, Jacob S, et al. Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy. Eur J Neurol. 2024;31:e16180. https:\/\/doi.org\/10.1111\/ene.16180.","journal-title":"Eur J Neurol"},{"key":"861_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.nmd.2019.12.003","volume":"30","author":"MR Tannemaat","year":"2020","unstructured":"Tannemaat MR, Verschuuren J. Emerging therapies for autoimmune myasthenia gravis: towards treatment without corticosteroids. Neuromuscul Disord. 2020;30:111\u20139. https:\/\/doi.org\/10.1016\/j.nmd.2019.12.003.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"861_CR8","volume":"28","author":"TLZ Chang","year":"2021","unstructured":"Chang TLZ, Hu XQ. China guidelines for the diagnosis and treatment of myasthenia gravis(2020 edition). Chin J Neuroimmunol Neurol. 2021;28(1):12.","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"861_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/WNF.0b013e31823c5480","volume":"35","author":"S Ito","year":"2012","unstructured":"Ito S, Masuda M, Tanaka S, et al. Low-dose glucocorticoid therapy complements the pituitary-adrenocortical system and reduces anxiety and insomnia in myasthenia gravis patients. Clin Neuropharmacol. 2012;35:30\u20136. https:\/\/doi.org\/10.1097\/WNF.0b013e31823c5480.","journal-title":"Clin Neuropharmacol"},{"key":"861_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.12659\/msm.902442","volume":"23","author":"G Qi","year":"2017","unstructured":"Qi G, Liu P, Dong H, et al. Metastatic thymoma-associated myasthenia gravis: favorable response to steroid pulse therapy plus immunosuppressive agent. Med Sci Monit. 2017;23:1217\u201323. https:\/\/doi.org\/10.12659\/msm.902442.","journal-title":"Med Sci Monit"},{"key":"861_CR11","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1007\/s00415-020-10264-0","volume":"268","author":"I Lotan","year":"2021","unstructured":"Lotan I, Hellmann MA, Wilf-Yarkoni A, et al. Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review. J Neurol. 2021;268:4573\u201386. https:\/\/doi.org\/10.1007\/s00415-020-10264-0.","journal-title":"J Neurol"},{"key":"861_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3389\/fnmol.2020.00156","volume":"13","author":"M Krenn","year":"2020","unstructured":"Krenn M, Grisold A, Wohlfarth P, et al. Pathomechanisms and clinical implications of myasthenic syndromes exacerbated and induced by medical treatments. Front Mol Neurosci. 2020;13:156. https:\/\/doi.org\/10.3389\/fnmol.2020.00156.","journal-title":"Front Mol Neurosci"},{"key":"861_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/s1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20:526\u201336. https:\/\/doi.org\/10.1016\/s1474-4422(21)00159-9.","journal-title":"Lancet Neurol"},{"key":"861_CR14","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1002\/acn3.52142","volume":"11","author":"S Luo","year":"2024","unstructured":"Luo S, Jiang Q, Zeng W, et al. Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China. Ann Clin Transl Neurol. 2024;11:2212\u201321. https:\/\/doi.org\/10.1002\/acn3.52142.","journal-title":"Ann Clin Transl Neurol"},{"key":"861_CR15","doi-asserted-by":"publisher","first-page":"28394","DOI":"10.1038\/s41598-024-79918-7","volume":"14","author":"J Ma","year":"2024","unstructured":"Ma J, Zhang H, Zhao J, et al. Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis. Sci Rep. 2024;14:28394. https:\/\/doi.org\/10.1038\/s41598-024-79918-7.","journal-title":"Sci Rep"},{"key":"861_CR16","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1007\/s00415-024-12556-1","volume":"271","author":"F Zhu","year":"2024","unstructured":"Zhu F, Wang WF, Ma CH, et al. Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod. J Neurol. 2024;271:5911\u20135. https:\/\/doi.org\/10.1007\/s00415-024-12556-1.","journal-title":"J Neurol"},{"key":"861_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s13023-024-03501-6","volume":"19","author":"W Yang","year":"2024","unstructured":"Yang W, Chen P, Guo J, et al. Clinical efficacy of efgartigimod combined with intravenous methylprednisolone in the acute phase of neuromyelitis optica spectrum disorders. Orphanet J Rare Dis. 2024;19:483. https:\/\/doi.org\/10.1186\/s13023-024-03501-6.","journal-title":"Orphanet J Rare Dis"},{"key":"861_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/s0140-6736(72)90520-x","volume":"1","author":"RB Jenkins","year":"1972","unstructured":"Jenkins RB. Treatment of myasthenia gravis with prednisone. Lancet. 1972;1:765\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(72)90520-x.","journal-title":"Lancet"},{"key":"861_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"RM Pascuzzi","year":"1984","unstructured":"Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15:291\u20138. https:\/\/doi.org\/10.1002\/ana.410150316.","journal-title":"Ann Neurol"},{"key":"861_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1212\/wnl.34.2.170","volume":"34","author":"A Sghirlanzoni","year":"1984","unstructured":"Sghirlanzoni A, Peluchetti D, Mantegazza R, et al. Myasthenia gravis: prolonged treatment with steroids. Neurology. 1984;34:170\u20134. https:\/\/doi.org\/10.1212\/wnl.34.2.170.","journal-title":"Neurology"},{"key":"861_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000116785","volume":"32","author":"A Evoli","year":"1992","unstructured":"Evoli A, Batocchi AP, Palmisani MT, et al. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol. 1992;32:37\u201343. https:\/\/doi.org\/10.1159\/000116785.","journal-title":"Eur Neurol"},{"key":"861_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000114612","volume":"12","author":"P Pinelli","year":"1974","unstructured":"Pinelli P, Tonali P, Scoppetta C. Long-term treatment of myasthenia gravis with alternate-day prednisone. Report on 15 patients. Eur Neurol. 1974;12:129\u201341. https:\/\/doi.org\/10.1159\/000114612.","journal-title":"Eur Neurol"},{"key":"861_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1136\/jnnp.68.2.214","volume":"68","author":"A Komiyama","year":"2000","unstructured":"Komiyama A, Arai H, Kijima M, et al. Extraocular muscle responses to high dose intravenous methylprednisolone in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2000;68:214\u20137. https:\/\/doi.org\/10.1136\/jnnp.68.2.214.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"861_CR24","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","volume":"97","author":"C Lindberg","year":"1998","unstructured":"Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand. 1998;97:370\u20133. https:\/\/doi.org\/10.1111\/j.1600-0404.1998.tb05968.x.","journal-title":"Acta Neurol Scand"},{"issue":"01","key":"861_CR25","first-page":"25","volume":"42","author":"WM Song","year":"2015","unstructured":"Song WM. Mechanism of early transient aggravation after glucocorticoid impact treatment in patients with myasthenia gravis. J Int Neurol Neurosurg. 2015;42(01):25.","journal-title":"J Int Neurol Neurosurg"},{"key":"861_CR26","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1136\/jnnp.41.5.394","volume":"41","author":"AK Lefvert","year":"1978","unstructured":"Lefvert AK, Bergstr\u00f6m K, Matell G, et al. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry. 1978;41:394\u2013403. https:\/\/doi.org\/10.1136\/jnnp.41.5.394.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"861_CR27","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE, et al. Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol. 2023;30:3854\u201367. https:\/\/doi.org\/10.1111\/ene.15872.","journal-title":"Eur J Neurol"},{"key":"861_CR28","doi-asserted-by":"publisher","first-page":"116740","DOI":"10.1016\/j.jns.2020.116740","volume":"412","author":"T Sugimotoa","year":"2015","unstructured":"Sugimotoa T, Ochib K, Ishikawaa R, et al. Initial deterioration and intravenous methylprednisolone therapy in patients with myasthenia gravis. J Neurol Sci. 2015;412:116740. https:\/\/doi.org\/10.1016\/j.jns.2020.116740.","journal-title":"J Neurol Sci"},{"key":"861_CR29","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/j.1552-4604.1994.tb01988.x","volume":"34","author":"JJ Ferry","year":"1994","unstructured":"Ferry JJ, Della-Coletta AA, Weber DJ, et al. Pilot study of the pharmacokinetics of methylprednisolone after single and multiple intravenous doses of methylprednisolone sodium succinate and methylprednisolone suleptanate to healthy volunteers. J Clin Pharmacol. 1994;34:1109\u201315. https:\/\/doi.org\/10.1002\/j.1552-4604.1994.tb01988.x.","journal-title":"J Clin Pharmacol"},{"key":"861_CR30","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1212\/01.wnl.0000138572.82125.f5","volume":"63","author":"SA Morrow","year":"2004","unstructured":"Morrow SA, Stoian CA, Dmitrovic J, et al. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology. 2004;63:1079\u201380. https:\/\/doi.org\/10.1212\/01.wnl.0000138572.82125.f5.","journal-title":"Neurology"},{"key":"861_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","volume":"44","author":"D Czock","year":"2005","unstructured":"Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44:61\u201398. https:\/\/doi.org\/10.2165\/00003088-200544010-00003.","journal-title":"Clin Pharmacokinet"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00861-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00861-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00861-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:51:55Z","timestamp":1768398715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00861-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["861"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00861-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shanshan Gu, Yongzhao Li, Huimin Dong, Hongxia Yang, Mei Ma, Mengna Li, Congya Yan, Pei Jia, Yaxuan Wang and Guoyan Qi declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures involving human subjects followed the ethical standards of the institutional and\/or national research committee and the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study protocol was approved by the Ethics Committees of Shijiazhuang People's Hospital (2024 [103]).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}